Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplat… Read more
Poniard Pharmaceuticals Inc (PARD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2011: -0.548x
Based on the latest financial reports, Poniard Pharmaceuticals Inc (PARD) has a cash flow conversion efficiency ratio of -0.548x as of September 2011.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.71 Million) by net assets ($3.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Poniard Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1989–2010)
This chart illustrates how Poniard Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Poniard Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poniard Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Circuit Research Labs Inc
PINK:CRLI
|
0.009x |
|
Colombia Energy Resources Inc
PINK:CERX
|
-0.281x |
|
Merriman Holdings Inc
PINK:MERR
|
0.067x |
|
Mansfelder Metals Ltd
PINK:MNSF
|
-0.123x |
|
Commerce Group Corp
PINK:CGCO
|
0.001x |
|
C=Holdings B.V
OTCGREY:CBUIF
|
N/A |
|
TFN Football Network
PINK:TFBN
|
7.932x |
|
EnerNorth Industries Inc
OTCGREY:ENYNF
|
0.120x |
Annual Cash Flow Conversion Efficiency for Poniard Pharmaceuticals Inc (1989–2010)
The table below shows the annual cash flow conversion efficiency of Poniard Pharmaceuticals Inc from 1989 to 2010.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2010-12-31 | $8.45 Million | $-24.28 Million | -2.872x | -91.32% |
| 2009-12-31 | $23.64 Million | $-35.49 Million | -1.501x | -113.58% |
| 2008-12-31 | $47.65 Million | $-33.49 Million | -0.703x | -154.02% |
| 2007-12-31 | $89.11 Million | $-24.65 Million | -0.277x | +24.90% |
| 2006-12-31 | $46.89 Million | $-17.27 Million | -0.368x | +92.90% |
| 2005-12-31 | $3.17 Million | $-16.47 Million | -5.190x | -518.37% |
| 2004-12-31 | $20.83 Million | $-17.48 Million | -0.839x | -508.70% |
| 2003-12-31 | $29.49 Million | $-4.07 Million | -0.138x | +84.27% |
| 2002-12-31 | $17.58 Million | $-15.41 Million | -0.877x | -97.57% |
| 2001-12-31 | $41.72 Million | $-18.51 Million | -0.444x | -62.12% |
| 2000-12-31 | $62.24 Million | $-17.04 Million | -0.274x | +54.89% |
| 1999-12-31 | $17.80 Million | $-10.80 Million | -0.607x | -417.51% |
| 1998-12-31 | $29.00 Million | $-3.40 Million | -0.117x | -35.03% |
| 1997-12-31 | $33.40 Million | $-2.90 Million | -0.087x | +81.21% |
| 1996-12-31 | $17.10 Million | $-7.90 Million | -0.462x | +31.16% |
| 1995-12-31 | $14.90 Million | $-10.00 Million | -0.671x | -2.95% |
| 1994-12-31 | $15.80 Million | $-10.30 Million | -0.652x | -115.69% |
| 1993-12-31 | $26.80 Million | $-8.10 Million | -0.302x | +24.44% |
| 1992-12-31 | $14.50 Million | $-5.80 Million | -0.400x | +61.29% |
| 1991-12-31 | $9.00 Million | $-9.30 Million | -1.033x | +16.67% |
| 1990-12-31 | $12.50 Million | $-15.50 Million | -1.240x | -27.97% |
| 1989-12-31 | $12.90 Million | $-12.50 Million | -0.969x | -- |